FDA generic biologics document delayed
Development of FDA background document on generic biologics is delayed while senior management addresses drug safety issues raised during the year. The goal of the document is to harmonize review practices of biologics used to treat different diseases; it was due out in 2004 (1"The Pink Sheet" Nov. 1, 2004, p. 16)...
You may also be interested in...
FDA is developing a background document as part of its ongoing action on "follow-on" biologics, Acting Commissioner for Operations Janet Woodcock, MD, said
The American Telemedicine Association backed use of more telehealth providers and changes to remote monitoring reimbursements in comments to the US Medicare agency.
STADA Strengthens Specialty Partnership Role Via US Filing